COST-EFFECTIVENESS OF BOCEPREVIR THERAPY IN ADULT PATIENTS WITH CHRONIC HEPATITIS C (HCV) GENOTYPE 1

被引：1
|
作者：
Mernagh, P. [1 ]
Feng, J. [1 ]
Del Cuore, M. [2 ]
机构：
[1] Optum, Sydney, NSW, Australia
[2] Merck Sharp & Dohme Australia, Sydney, NSW, Australia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.440
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A94 / A94
页数：1
相关论文
共 50 条
  • [31] THE COST-EFFECTIVENESS OF TREATMENTS IN NON-CIRRHOTIC SAUDI ARABIAN PATIENTS WITH GENOTYPE 1 AND GENOTYPE 4 CHRONIC HEPATITIS C
    Alowairdhi, M.
    VALUE IN HEALTH, 2018, 21 : S84 - S84
  • [32] Cost-effectiveness of Sofosbuvir plus Ledipasvir Antiviral Treatment for Elderly Patients with Chronic Hepatitis C Genotype 1
    Ciaccio, Antonio
    Cortesi, Paolo
    Bellelli, Giuseppe
    Rota, Matteo
    Rota, Monica
    Mantovani, Lorenzo G.
    Annoni, Giorgio
    Strazzabosco, Mario
    HEPATOLOGY, 2015, 62 : 919A - 919A
  • [33] Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
    Brogan, Anita J.
    Talbird, Sandra E.
    Thompson, James R.
    Miller, Jeffrey D.
    Rubin, Jaime
    Deniz, Baris
    PLOS ONE, 2014, 9 (03):
  • [34] Evaluating the cost-effectiveness of using boceprevir and telaprevir in the treatment of newly diagnosed Hepatitis C genotype 1 patients: A payer's perspective.
    Jalundhwala, Yash J.
    Patel, Pankaj
    Nancy, Hedlund
    Wendy, Cheng
    Beenish, Manzoor
    Haridarshan, Patel
    Touchette, Daniel
    PHARMACOTHERAPY, 2012, 32 (10): : E300 - E301
  • [35] Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients
    Gimeno-Ballester, Vicente
    Mar, Javier
    O'Leary, Aisling
    Adams, Roisin
    San Miguel, Ramon
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (01) : 85 - 93
  • [36] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER 'REAL-LIFE' CONDITIONS
    Ruiz-Antoran, B.
    Sancho-Lopez, A.
    Payares, C.
    de la Revilla, J.
    Calleja Panero, J. L.
    Avendano-Sola, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 18 - 18
  • [37] COST-EFFECTIVENESS ANALYSIS OF TRIPLE THERAPY WITH PEGINTERFERON, RIBAVIRIN, AND BOCEPREVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS GENOTYPE 1 WITH SEVERE FIBROSIS UNDER "REAL-LIFE" CONDITIONS
    Ruiz-Antoran, B.
    Pascasio, J. M.
    Gea, F.
    Barcena, R.
    Larrubia, J.
    Perez Alvarez, R.
    Sousa, J.
    Romero-Gomez, Manuel
    Sola, R.
    de la Revilla, J.
    Crespo, J.
    Navarro, J.
    Arenas, J.
    Delgado, M.
    Fernandez Rodriguez, C.
    Planas, R.
    Buti, M.
    Forns, X.
    Calleja, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A367 - A367
  • [38] Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Lin, Liang
    Teng, Monica
    Koh, Calvin J.
    Lim, Seng Gee
    Lim, Boon Peng
    Dan, Yock Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (09) : 1628 - 1637
  • [39] COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN SCOTLAND
    Dillon, J.
    Treharne, C.
    Howells, R.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S635 - S635
  • [40] COST-EFFECTIVENESS OF TELAPREVIR IN GENOTYPE 1 CHRONIC HEPATITIS-C VIRUS INFECTION IN VENEZUELA
    Garcia Marti, S.
    Alcaraz, A.
    Valanzasca, P.
    Garay, O. U.
    McMullen, M.
    Rey Ares, L.
    Obando, C. A.
    Caporale, J.
    VALUE IN HEALTH, 2013, 16 (07) : A714 - A714
12345